MX2019003684A - Formas cristalinas de un derivado de acido biliar. - Google Patents
Formas cristalinas de un derivado de acido biliar.Info
- Publication number
- MX2019003684A MX2019003684A MX2019003684A MX2019003684A MX2019003684A MX 2019003684 A MX2019003684 A MX 2019003684A MX 2019003684 A MX2019003684 A MX 2019003684A MX 2019003684 A MX2019003684 A MX 2019003684A MX 2019003684 A MX2019003684 A MX 2019003684A
- Authority
- MX
- Mexico
- Prior art keywords
- bile acid
- acid derivative
- crystalline forms
- crystalline
- bile
- Prior art date
Links
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical class C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 title 1
- 239000003613 bile acid Substances 0.000 abstract 1
- -1 bile acid compound Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662402813P | 2016-09-30 | 2016-09-30 | |
| PCT/US2017/054227 WO2018064441A1 (en) | 2016-09-30 | 2017-09-29 | Crystalline forms of a bile acid derivative |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019003684A true MX2019003684A (es) | 2019-08-05 |
Family
ID=61760943
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019003684A MX2019003684A (es) | 2016-09-30 | 2017-09-29 | Formas cristalinas de un derivado de acido biliar. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20200024299A1 (enExample) |
| EP (1) | EP3518937A4 (enExample) |
| JP (1) | JP2019529481A (enExample) |
| KR (1) | KR20190057108A (enExample) |
| CN (1) | CN109963567A (enExample) |
| AU (1) | AU2017336803A1 (enExample) |
| BR (1) | BR112019006242A2 (enExample) |
| CA (1) | CA3038534A1 (enExample) |
| IL (1) | IL265621A (enExample) |
| MX (1) | MX2019003684A (enExample) |
| WO (1) | WO2018064441A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021071837A1 (en) | 2019-10-07 | 2021-04-15 | Kallyope, Inc. | Gpr119 agonists |
| TW202140440A (zh) | 2020-02-28 | 2021-11-01 | 美商克力歐普股份有限公司 | Gpr40激動劑 |
| EP4153589A4 (en) | 2020-05-19 | 2024-06-12 | Kallyope, Inc. | AMPK ACTIVATORS |
| WO2021263039A1 (en) | 2020-06-26 | 2021-12-30 | Kallyope, Inc. | Ampk activators |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2040713T3 (pl) * | 2006-06-27 | 2014-11-28 | Intercept Pharmaceuticals Inc | Pochodne kwasów żółciowych jako ligandy FXR do zapobiegania lub leczenia chorób lub stanów, w których pośredniczy FXR |
| ES2559521T3 (es) * | 2006-10-16 | 2016-02-12 | Thesan Pharmaceuticals, Inc. | Pirazolil tienopiridinas terapéuticas |
| WO2009051112A1 (ja) * | 2007-10-15 | 2009-04-23 | Takeda Pharmaceutical Company Limited | アミド化合物およびその用途 |
| EP2468762A1 (en) * | 2010-11-30 | 2012-06-27 | Dr. Falk Pharma Gmbh | Optimized synthesis of pure, non-polymorphic, crystalline bile acids with defined particle size |
| PT3336097T (pt) * | 2012-06-19 | 2020-10-29 | Intercept Pharmaceuticals Inc | Preparação da forma não cristalina de ácido obeticólico |
| CN108250264A (zh) * | 2012-10-26 | 2018-07-06 | 英特塞普特医药品公司 | 制备胆汁酸衍生物的方法 |
| NZ708501A (en) * | 2012-11-28 | 2019-03-29 | Intercept Pharmaceuticals Inc | Treatment of pulmonary disease |
| HUP1300504A2 (en) * | 2013-08-27 | 2015-03-30 | Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag | Sorafenib salts |
| US10604544B2 (en) * | 2015-08-07 | 2020-03-31 | Intercept Pharmaceuticals, Inc. | Methods for preparation of bile acids and derivatives thereof |
| KR20180052756A (ko) * | 2015-09-24 | 2018-05-18 | 인터셉트 파마슈티컬즈, 인크. | 담즙산 유도체 제조를 위한 방법 및 중간체 |
-
2017
- 2017-09-29 BR BR112019006242A patent/BR112019006242A2/pt not_active IP Right Cessation
- 2017-09-29 EP EP17857474.5A patent/EP3518937A4/en not_active Withdrawn
- 2017-09-29 WO PCT/US2017/054227 patent/WO2018064441A1/en not_active Ceased
- 2017-09-29 AU AU2017336803A patent/AU2017336803A1/en not_active Abandoned
- 2017-09-29 US US16/337,982 patent/US20200024299A1/en not_active Abandoned
- 2017-09-29 JP JP2019516972A patent/JP2019529481A/ja not_active Withdrawn
- 2017-09-29 CA CA3038534A patent/CA3038534A1/en not_active Abandoned
- 2017-09-29 KR KR1020197012131A patent/KR20190057108A/ko not_active Withdrawn
- 2017-09-29 CN CN201780071347.7A patent/CN109963567A/zh active Pending
- 2017-09-29 MX MX2019003684A patent/MX2019003684A/es unknown
-
2019
- 2019-03-26 IL IL265621A patent/IL265621A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20200024299A1 (en) | 2020-01-23 |
| EP3518937A4 (en) | 2020-04-29 |
| BR112019006242A2 (pt) | 2019-06-18 |
| KR20190057108A (ko) | 2019-05-27 |
| EP3518937A1 (en) | 2019-08-07 |
| IL265621A (en) | 2019-05-30 |
| CN109963567A (zh) | 2019-07-02 |
| JP2019529481A (ja) | 2019-10-17 |
| CA3038534A1 (en) | 2018-04-05 |
| WO2018064441A1 (en) | 2018-04-05 |
| AU2017336803A1 (en) | 2019-04-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL304455A (en) | Methods and intermediates for the preparation of bile acid derivatives | |
| EP3248967A4 (en) | A novel crystalline form of a benzimidazole derivative and a preparation method thereof | |
| WO2015117081A3 (en) | Methods and compositions for treatment of a beta thalessemia | |
| AU2017435893B2 (en) | Methods for the administration of certain VMAT2 inhibitors | |
| EP3150600A4 (en) | Dihydropyrimido loop derivative as hbv inhibitor | |
| AU2016315655A8 (en) | Ochrobactrum-mediated transformation of plants | |
| EP3136857A4 (en) | Crystalline form of baricitinib | |
| IN2014CH00247A (enExample) | ||
| EP3244725A4 (en) | Growth of cryo-sprouts | |
| EP3176173A4 (en) | Crystalline free bases of c-met inhibitor or crystalline acid salts thereof, and preparation methods and uses thereof | |
| EP3370728A4 (en) | PROCESS FOR THE PREPARATION OF OBETICHOLIC ACID AND DERIVATIVES THEREOF | |
| IN2013MU00646A (enExample) | ||
| IL257223A (en) | New crystalline form and acetic acid adducts of palbociclib | |
| EP3215132A4 (en) | Methods of administering amantadine compositions | |
| EP3141540A4 (en) | Crystalline form of chlorogenic acid and preparation method therefor | |
| MX2019003684A (es) | Formas cristalinas de un derivado de acido biliar. | |
| EP3110415A4 (en) | Compositions and methods for inhibition of mycobacteria | |
| EP3532055A4 (en) | COMPOSITIONS AND PROCESSES FOR THE PRODUCTION OF COMPOUNDS | |
| EP3530650A4 (en) | CRYSTALLINE FORM OF (R) -4-HYDROXY-2-OXO-1-PYRROLIDINE ACETAMIDE, PRODUCTION METHOD THEREFOR, AND USE THEREOF | |
| EP3327012A4 (en) | Crystalline forms of bilastine and preparation methods thereof | |
| MX2019010640A (es) | Formas cristalinas de acido obeticolico. | |
| EP3202404A4 (en) | Oral formulation of a-nor-5 androstane compound | |
| EP3235822A4 (en) | Novel bisphosphonic acid derivative and application for same | |
| EP3188737A4 (en) | Crystalline form of eltrombopag free acid | |
| EP3130593A4 (en) | Phenanthroline phosphonic acid derivative and preparation method therefor and application thereof |